Name (Synonyms) | Correlation | |
---|---|---|
drug119 | AZD5718 Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D051436 | Renal Insufficiency, Chronic NIH | 0.45 |
D007674 | Kidney Diseases NIH | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012622 | Chronic kidney disease HPO | 0.45 |
HP:0000077 | Abnormality of the kidney HPO | 0.35 |
There is one clinical trial.
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
Description: To evaluate the dose-response effect of AZD5718 on urine ACR at 20 weeks
Measure: Change from baseline in urine albumin to creatinine ratio (ACR) to Week 20 Time: Week 1 to Week 20Description: To evaluate the dose-response effect of AZD5718 on urine ACR at 12 weeks
Measure: Change from baseline in urine ACR to Week 12 Time: Week 1 to Week 12Description: To assess the safety and tolerability profile of AZD5718 treatment
Measure: Number of participants with adverse events and serious adverse events Time: Screening to Week 24Description: To evaluate the effect of AZD5718 on ambulatory blood pressure
Measure: Change from baseline in 24-hours mean systolic blood pressure to Week 12 Time: Week 1 to Week 12Description: To assess the PK of AZD5718 after repeated oral dosing for 20 weeks
Measure: Plasma concentrations of AZD5718 Time: Week 2 to Week 20Description: To assess the effect of AZD5718 on renal function
Measure: Change from baseline in estimated glomerular filtration rate (eGFR) to Week 12 Time: Week 1 to Week 12